Our Strategy

Our proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Our lead product candidate, entospletinib (ENTO), is a selective spleen tyrosine kinase (SYK) inhibitor that has been tested in over 170 acute myeloid leukemia (AML) patients to date. Based on clinical results in a biomarker-defined patient subset we plan to initiate a registrational clinical trial in 2021. We are also developing KB-0742, a selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) for the treatment of MYC-amplified solid tumors. We expect to submit an Investigational New Drug (IND) application for KB-0742 in the fourth quarter of 2020. In addition, we have multiple oncology discovery programs targeting dysregulated transcription factors.

Our Science:

Targeting dysregulated transcription factors in cancer

Addressing the complexity of oncogenic TRNs requires a sophisticated and holistic approach to targeting cancer biology. TRNs encompass hundreds of proteins that function in a coordinated fashion to orchestrate specific gene expression programs that control development and function of healthy cells. Dysregulated TRNs resulting from aberrant transcription factor expression or activity are frequently responsible for reprogramming healthy cells into cancerous tumor cells. We apply computational biology to map the TRNs and identify the critical nodes and gene expression signatures that drive cancer. We believe that these critical nodes present attractive targets for therapeutic intervention using a biomarker-driven precision medicine strategy.

Product Engine

Our product engine includes four interconnected components, each of which is informed by our translational expertise, that enable efficient, hypothesis-driven clinical development of our product candidates:

map icon
screen icon
optimize icon
validate

Identify gene expression signature of selective TRN modulation

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

Refine pharmacological properties to yield attractive product development candidates

Hypothesis driven clinical trials to deliver proof of concept early in the development process

map icon

Identify gene expression signature of selective TRN modulation​

screen icon

Conduct high throughput SMM screens in tumor cell lysates to identify selective TRN modulators

optimize icon

Refine pharmacological properties to yield attractive development candidates

validate

Hypothesis driven clinical trials to deliver proof of concept early in the development process

Pipeline/Programs

We have developed a robust clinical and preclinical pipeline through a combination of internal discovery efforts and focused asset acquisition. The following chart summarizes our product pipeline, including our lead product candidate, ENTO, as well as our discovery programs and our next anticipated milestones.

Product Candidate

Discovery

IND-Enabling Studies

Phase 1 Trial

Phase 2 Trial

Phase 3 Trial

Next Anticipated Milestone

2021: Initiate NPM1 mt AML registrational Phase 2/3 clinical trial pending regulatory feedback from planned meetings

2021: Initiate FLT3 mt AML Phase 1/2 clinical trial

TRN

Indication

Discovery

IND-Enabling Studies

Phase 1 Trial

Phase 2 Trial

Phase 3 Trial

Next Anticipated Milestone

MYB

AML

First IND filing in 2022 among these programs

ARv7

Prostate Cancer

IRF4

Multiple Myeloma

ASCL1

Small Cell / Neuroendocrine Cancers

Color Band

Careers

JOIN OUR TEAM

woman in lab
woman in lab
woman in lab

We are looking for innovative team members who share our passion for transformative science paired with unparalleled execution.

See our current list of openings below or submit your resume to careers@kronosbio.com.

we’re building the highway, not filling potholes”

‟we’re building the highway, not filling potholes”

marius_pop
Marius Pop
Director, Biology